Clinical trial
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of…
NCT00360360 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00360360 |
|---|---|
| Title | Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site |
| Official title | A Phase II Study of Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Patients With Carcinoma of Unknown Primary Site |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasm, Unknown Primary |
| Intervention type | Drug |
| Interventions | paclitaxel, carboplatin, bevacizumab, erlotinib |
| Enrollment | 60 |
| Start date | Jul 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Aug 4, 2006 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: